Share this article
Share this article
WOBURN, Mass., March 9, 2021 /PRNewswire/ Today, Eirion Therapeutics, Inc., an aesthetic dermatology company headquartered in Woburn, Massachusetts, announced a deal with Shanghai Haohai Biological Technology Ltd. ( Haohai ) that will result in a $32 million Series A Preferred Stock investment into Eirion along with exclusive licenses that will be for all of Eirion s products for the territory of China in exchange for an upfront payment in the amount of $8 million. The deal is structured in segments over the next approximately 18 months. Haohai is a leading Chinese aesthetic medicine company headquartered in Shanghai and is publicly traded on the Hong Kong (6826.HK) and Shanghai (688366.SS) stock exchanges.
Eirion Therapeutics, Inc Closes $40 Million Series A Investment and Licensing Deal with Shanghai Haohai Biological Technology Ltd benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.